对于阿尔茨海默氏症的光疗法最近的进展:关于设计,合成和性能的全面调查
Telmo N Francisco1, Daniela Malafaia1, Lúcia Melo1
1LAQV-REQUIMTE, Department of Chemistry, University of Aveiro, Campus de Santiago, 3810-193 Aveiro, Portugal.
ACS omega
|April 1, 2024
概括
小分子光疗法可为阿尔茨海默病 (AD) 提供双重诊断和治疗效益. 这些先进的化合物承诺可访问的查和个性化治疗,超越当前的局限性.
科学领域:
- 神经退行性疾病 神经退行性疾病
- 分子成像学分子成像学
- 药物发现 药物发现 药物发现
背景情况:
- 阿尔茨海默病 (AD) 带来了重大的诊断和治疗挑战,由于增加预期寿命,影响全球健康.
- 目前的阿尔茨海默病诊断 (例如PET射线追踪器) 和治疗方法的局限性突显出需要创新的解决方案.
- 最近的进展,包括单克隆抗体,重新振兴了对AD小分子药物发现的兴趣.
研究的目的:
- 对阿尔茨海默氏病的小分子近红外光疗法近红外光疗法的最新进展进行审查.
- 详细介绍这些神经复杂剂的设计,合成和特性.
- 提供全面的概述,以指导未来的临床开发.
主要方法:
- 关于阿尔茨海默病的光疗法目前文献的综述.
- 分析设计策略和合成方法的分析,用于小分子透视学.
- 在体外和体内成像和治疗性质的评估.
主要成果:
- 小分子治疗术为AD提供了同时的诊断和治疗能力.
- 这些药物显示出具有成本效益,可访问的成像,补充或取代PET扫描的潜力.
- 光疗法在阿尔茨海默病患者护理中促进了个性化医疗方法.
结论:
- 小分子光疗法代表了改善AD诊断和治疗的有希望的途径.
- 这些化合物的进一步开发可能会导致更有效和更容易获得的临床应用.
- 这次审查是一个里程碑,鼓励继续研究阿尔茨海默病的治疗学.
相关概念视频
Alzheimer's Disease: Overview
469
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
469
Alzheimer's Disease: Treatment
184
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
184


